non-Hodgkin lymphoma
Nemtabrutinib Shows Promise for Relapsed CLL and NHL
The Bruton’s tyrosine kinase (BTK) inhibitor nemtabrutinib (Merck) may offer a new treatment option for ...
NOVEMBER 21, 2023
The Case for Switching to Rituximab Biosimilar
Switching from originator rituximab to rituximab-abbs can save an institution up to $13,000 annually per patient ...
FEBRUARY 16, 2022
Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% ...
DECEMBER 28, 2021
FDA Approves Truxima, First Biosimilar to Rituxan
The FDA approved rituximab-abbs (Truxima, Celltrion/Teva), the first biosimilar to rituximab (Rituxan, ...
DECEMBER 1, 2018
CAR T-Cell Therapy Roundup
The field of CAR therapy has been heating up, with the recent approval of Novartis’ tisagenlecleucel ...
SEPTEMBER 21, 2017
Dr. Craig Portell Discusses Clinical Updates Related to NHL
At the 2017 Community Oncology Alliance meeting, Craig Portell, MD, at the Emily Couric Cancer Center at University ...
MAY 31, 2017
CAR T-Cell Study in NHL Patients Shows Activity and Feasibility
San Diego—Once again, a study has found that chimeric antigen receptor (CAR) T cells have impressive activity ...
APRIL 5, 2017
Obinutuzumab Increased OS In Refractory Indolent NHL Pts
San Diego—Obinutuzumab plus bendamustine followed by obinutuzumab maintenance provides an overall survival ...
FEBRUARY 9, 2017
HBV/HCV Coinfection Are Risk Factors for Non-Hodgkin Lymphoma in HIV Patients
Chronic hepatitis B and C virus (HBV/HCV) infection is associated with an increased risk for non-Hodgkin lymphoma ...
OCTOBER 23, 2016
CAR T-Cell Protocol Led to High Response Rates in NHL
Very good response rates, including high complete response (CR) rates, were reported in patients with non-Hodgkin ...
OCTOBER 6, 2016
